Kidney Cancers3DBloodNCT07820566
Development of a Preclinical 3D Vascularized and Perfused Tumoroid Model in Oncology and Urology Developed From Patient Tumors (Kidney, Bladder, and Prostate Cancers)
An observational study of Kidney Cancers and Bladder Cancer, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
This is a study : Single-center Prospective Translational Based on data and blood samples. In this context, the aim is to collect approximately 10 ml of blood from each patient included in the 3D tumoroid development project. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Kidney Cancers, Bladder Cancer, Prostate Cancer
- What is being tested?
- Blood sample
- How many people
- 100 participants
- Where
- 1 siteFrance
- Study dates
- 2 Sep 2024to Sep 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: * Male or female subject (≥18 years old); * Diagnosed with kidney cancer, prostate cancer, or bladder cancer; * whose tumor tissue and associated data are reused as part of the SphéroUro protocol (study outside the Jardé law, retrospective study on tumor tissue and associated data, from the biobank registered with the Ministry of Education and Research under reference No. DC 2016-2677)
Who may be able to join
- Criteria common to all patients:
- Male or female subject (≥18 years old);
- Diagnosed with kidney cancer, prostate cancer, or bladder cancer;
- whose tumor tissue and associated data are reused as part of the SphéroUro protocol (study outside the Jardé law, retrospective study on tumor tissue and associated data, from the biobank registered with the Ministry of Education and Research under reference No. DC 2016-2677);
- affiliated with a social security health insurance scheme or beneficiary of such a scheme;
- agreeing to participate in the 3DBlood study.
Show all 10Show fewer
- Specific criteria for patients with renal cell carcinoma (RCC):
- Extended nephrectomy (EN) (larger tumor, closer to the sinus; therefore at greater risk of metastasis): with a cavo, cavectomy (neoplastic thrombus in the vena cava), or renal vein bud, or lymph node dissection, or with adrenalectomy (often for tumors, therefore possible metastases).
- Or
- Partial nephrectomy (PN): with tumors at stage T2 or T3a)
Who cannot join
- Patient refusal to participate in the study;
- Inability to provide the subject with informed consent (subject in an emergency situation, difficulties in understanding the subject, etc.);
- Patient under legal protection, guardianship, or conservatorship;
- Patient currently participating in a therapeutic clinical trial (i.e., gene therapy or other).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service de Chirurgie Urologique _ Hôpitaux Universitaires de Strasbourg
Strasbourg, 67091
Hervé LANG, PUPH, 33 3 69 55 09 74, herve.lang@chru-strasbourg.fr
Hervé LANG, PUPH
About this study
This is a study :
- Single-center
- Prospective
- Translational
- Based on data and blood samples. In this context, the aim is to collect approximately 10 ml of blood from each patient included in the 3D tumoroid development project.
The main objective is to establish and validate a panel of vascularized and perfused 3D tumoroids for personalized medicine based on patient tumors for urological cancers, incorporating autologous immune cells.
Translated with DeepL.com (free version)
- Conditions
- Kidney Cancers, Bladder Cancer, Prostate Cancer
- Being tested
- Blood sample
- Medical subject headings
- Kidney Neoplasms, Urinary Bladder Neoplasms, Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood sampleBiological
An additional 10 ml blood sample taken during a routine blood test
What is being measured
The primary outcome is the main question the study is designed to answer.
Constitute and validate a panel of vascularized and perfused 3D tumoroids for personalized medicine based on patient tumors for urological cancers, incorporating autologous immune cells.
For the establishment of the models, it is necessary to have: sufficient cell viability after enzymatic dissociation of the tissues and a correspondence of patient/model 3D therapeutic responses. The patients' blood will be collected to isolate immune cells using a Ficoll gradient, to integrate them into the forming 3D structures, taking into account the proportion present in the primary tumor tissues of each patient, for the 3D structures developed from their tumor.
Measured: Day 1 after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2026
- Study start2 Sep 2024
- Primary completionSep 2029 (estimated)
- Study completionSep 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Kidney CancersStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07820566
- Sponsor's protocol ID
- 9310
- Acronym
- 3DBlood
- Status last verified
- Jan 2026
- First submitted
- 5 Jan 2026
- Last updated
- 15 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development of a Preclinical 3D Vascularized and Perfused Tumoroid Model in Oncology and Urology Developed From Patient Tumors (Kidney, Bladder, and Prostate Cancers)
- ClinicalTrials.gov ID
- NCT07820566
- Acronym / sponsor ID
- 3DBlood / 9310
- Conditions
- Kidney Cancers, Bladder Cancer, Prostate Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 2 Sep 2024 (actual)
- Primary completion
- Sep 2029 (estimated)
- Study completion
- Sep 2029 (estimated)
- First posted
- 15 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a study :
- Single-center
- Prospective
- Translational
- Based on data and blood samples. In this context, the aim is to collect approximately 10 ml of blood from each patient included in the 3D tumoroid development project.
The main objective is to establish and validate a panel of vascularized and perfused 3D tumoroids for personalized medicine based on patient tumors for urological cancers, incorporating autologous immune cells.
Translated with DeepL.com (free version)
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- * Male or female subject (≥18 years old); * Diagnosed with kidney cancer, prostate cancer, or bladder cancer; * whose tumor tissue and associated data are reused as part of the SphéroUro protocol (study outside the Jardé law, retrospective study on tumor tissue and associated data, from the biobank registered with the Ministry of Education and Research under reference No. DC 2016-2677)
Key inclusion criteria (10 listed)
- Criteria common to all patients:
- Specific criteria for patients with renal cell carcinoma (RCC):
- Or
- Partial nephrectomy (PN): with tumors at stage T2 or T3a)
Key exclusion criteria (4 listed)
- Patient refusal to participate in the study;
- Inability to provide the subject with informed consent (subject in an emergency situation, difficulties in understanding the subject, etc.);
- Patient under legal protection, guardianship, or conservatorship;
- Patient currently participating in a therapeutic clinical trial (i.e., gene therapy or other).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood sampleAn additional 10 ml blood sample taken during a routine blood test | Biological | – |
Primary outcome
Constitute and validate a panel of vascularized and perfused 3D tumoroids for personalized medicine based on patient tumors for urological cancers, incorporating autologous immune cells.
Time frame: Day 1 after surgery
For the establishment of the models, it is necessary to have: sufficient cell viability after enzymatic dissociation of the tissues and a correspondence of patient/model 3D therapeutic responses. The patients' blood will be collected to isolate immune cells using a Ficoll gradient, to integrate them into the forming 3D structures, taking into account the proportion present in the primary tumor tissues of each patient, for the 3D structures developed from their tumor.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2026.
Related trials for Kidney Cancers
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
RecruitingPhase 2/3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
Not yet recruitingPhase 2
Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer
Nonmetastatic Locally Advanced Non-Clear Cell Renal Cell Carcinoma
Not yet recruitingPhase 1
A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment
Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Kidney Cancers and Bladder Cancer, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hervé LANG, PUPH (33369550974, Herve.Lang@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Constitute and validate a panel of vascularized and perfused 3D tumoroids for personalized medicine based on patient tumors for urological cancers, incorporating autologous immune cells. (time frame: Day 1 after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2026.